After A Freefall In Axovant Shares, Chardan Upgrades
January 10, 2018 at 11:45 AM EST
Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|